Scholarlink

<p>Currently, accessible objective indicators for predicting the prognosis and treatment outcomes of non-small cell lung cancer (NSCLC) are lacking. This study investigates the potential of T lymphocyte subsets and mitochondrial biomarkers as predictors of metastasis and evaluators of therapy response in advanced NSCLC. We analyzed clinical data from 24 advanced NSCLC patients, including T-cell counts and mitochondrial mass (MM)/membrane potential (MMP) measurements. Group comparisons used parametric t-tests and non-parametric Mann-Whitney U tests, with False Discovery Rate (FDR) correction for multiple comparisons. Predictive performance was evaluated via receiver operating characteristic (ROC) curves (area under curve, AUC). CD8 + T cells with low mitochondrial membrane potential (MMP-Low) and CD8 + T-cell mitochondrial mass (MM) showed promising potential in predicting metastasis (AUC = 0.85 and 0.87). Three T-cell biomarkers correlated with therapeutic outcomes (<i>p</i> &lt; 0.05): PD-1 + CD8 + T-cell percentage, MMP-Low CD8 + T-cell proportion, CD8 + T-cell MM levels. Our exploratory findings suggest that T lymphocyte subsets and mitochondrial indices show potential as biomarkers to evaluate therapy response and predict metastasis risk in advanced NSCLC, which may facilitate individualized treatment and timely regimen adjustment for patients pending further validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

T lymphocyte subsets and mitochondrial index predict outcomes in advanced non small cell lung cancer therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月31日

查看全文
  • Zhengming Huang,
  • Chiqing Ying,
  • Dan Zhu

摘要

Currently, accessible objective indicators for predicting the prognosis and treatment outcomes of non-small cell lung cancer (NSCLC) are lacking. This study investigates the potential of T lymphocyte subsets and mitochondrial biomarkers as predictors of metastasis and evaluators of therapy response in advanced NSCLC. We analyzed clinical data from 24 advanced NSCLC patients, including T-cell counts and mitochondrial mass (MM)/membrane potential (MMP) measurements. Group comparisons used parametric t-tests and non-parametric Mann-Whitney U tests, with False Discovery Rate (FDR) correction for multiple comparisons. Predictive performance was evaluated via receiver operating characteristic (ROC) curves (area under curve, AUC). CD8 + T cells with low mitochondrial membrane potential (MMP-Low) and CD8 + T-cell mitochondrial mass (MM) showed promising potential in predicting metastasis (AUC = 0.85 and 0.87). Three T-cell biomarkers correlated with therapeutic outcomes (p < 0.05): PD-1 + CD8 + T-cell percentage, MMP-Low CD8 + T-cell proportion, CD8 + T-cell MM levels. Our exploratory findings suggest that T lymphocyte subsets and mitochondrial indices show potential as biomarkers to evaluate therapy response and predict metastasis risk in advanced NSCLC, which may facilitate individualized treatment and timely regimen adjustment for patients pending further validation.